NIH R01 · 2025
Ubiquitin D as a potential therapeutic target for NASH, HCC and chronic kidney diseases
Abstract: Non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease (NAFLD), is one of the major causes of cirrhosis and hepatocellular carcinoma (HCC). There is currently no approved treatment for NASH and patients with advanced fibrosis are at highest risk of mortality due to cardiovascular diseases (CVD). Furthermore, presence of NAFLD increases the risk of chronic kidney disease (CKD) by about 80%. It is not known how NASH and CKD influence each other, but together they can influence CVD and patient mortality. Therefore, a therapeutic target that can improve NASH and its associated co-morbidities such as CKD and CVD will be of great benefit in clinics.…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.
← All labs at Sanford Burnham Prebys Medical Discovery Institute